World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
34209
World Ranking
15405
National Ranking
7768

Overview

Sandro Pignata is affiliated with the National Cancer Institute in the United States. Their research primarily focuses on medicine, with a strong emphasis on oncology, reproductive medicine, pulmonary and respiratory medicine, obstetrics and gynecology, and surgery.

The scientist's work centers on several main topics, including:

  • Ovarian cancer diagnosis and treatment
  • PARP inhibition in cancer therapy
  • Endometrial and cervical cancer treatments
  • Cancer immunotherapy and biomarkers
  • BRCA gene mutations in cancer
  • Renal cell carcinoma treatment
  • Cancer genomics and diagnostics

Among recent papers associated with Sandro Pignata are:

  • "Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial," 2021, The Lancet Oncology
  • "Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study," 2021, The Lancet Oncology
  • "Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)," 2021, Journal of Clinical Oncology
  • "The forefront of ovarian cancer therapy: update on PARP inhibitors," 2020, Annals of Oncology
  • "Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study," 2023, Journal of Clinical Oncology

Frequent co-authors include:

  • Domenica Lorusso
  • Nicoletta Colombo
  • Giovanni Scambia
  • Ugo De Giorgi
  • Carmela Pisano

Publications by Sandro Pignata frequently appear in the following venues:

  • Journal of Clinical Oncology (41 publications)
  • International Journal of Gynecological Cancer (40 publications)
  • Annals of Oncology (37 publications)
  • Gynecologic Oncology (30 publications)
  • ESMO Open (16 publications)

Best Publications

  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Eric Pujade-Lauraine;Jonathan A Ledermann;Frédéric Selle;Val Gebski

  • Radiofrequency Ablation of Unresectable Primary and Metastatic Hepatic Malignancies: Results in 123 Patients

    Steven A. Curley;Francesco Izzo;Paolo Delrio;Lee M. Ellis

  • Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

    Isabelle Ray-Coquard;Patricia Pautier;Sandro Pignata;David Pérol

  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Robert L Coleman;Amit M Oza;Domenica Lorusso;Carol Aghajanian

  • A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients

    Giuseppe Manghisi;Silvana Elba;Ascanio Mossa;Antonio Giorgio

  • ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

    N. Colombo;C. Sessa;A. du Bois;J. Ledermann

  • The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer.

    David Cibula;Richard Pötter;François Planchamp;Elisabeth Avall-Lundqvist

  • Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

    Eric Pujade-Lauraine;Uwe Wagner;Elisabeth Aavall-Lundqvist;Val Gebski

  • Prospective validation of the CLIP score, a new prognostic system for cirrhotic patients with hepatocellular carcinoma (RE: Hepatology 2000, 32/3: 679-80)

    Izzo Francesco;Oreste Cuomo;Gaetano Capuano;Giuseppe Ruggiero

  • Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

    U.A. Matulonis;R. Shapira-Frommer;A.D. Santin;A.S. Lisyanskaya

  • Early and Late Complications After Radiofrequency Ablation of Malignant Liver Tumors in 608 Patients

    Steven A. Curley;Paolo Marra;Karen Beaty;Lee M. Ellis

  • Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.

    Sandro Pignata;Giovanni Scambia;Dionyssios Katsaros;Ciro Gallo

  • Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer

    Andreas Du Bois;Anne Floquet;Jae Weon Kim;Jae Weon Kim;Joern Rau

  • Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer

    Gabriella Ferrandina;Manuela Ludovisi;Domenica Lorusso;Sandro Pignata

  • Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

    Robert L Coleman;Domenica Lorusso;Christine Gennigens;Antonio González-Martín

  • The forefront of ovarian cancer therapy: update on PARP inhibitors.

    M.R. Mirza;R.L. Coleman;A. González-Martín;K.N. Moore

  • Treatment of recurrent ovarian cancer

    Sandro Pignata;S. C. Cecere;A. Du Bois;P. Harter

  • Tamoxifen in treatment of hepatocellular carcinoma: A randomised controlled trial

    Ciro Gallo;B. Daniele;G. B. Gaeta;F. Perrone

  • ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.

    N Colombo;N Colombo;C Sessa;A du Bois;J Ledermann

  • Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial

    Andrés Poveda;Anne Floquet;Jonathan A. Ledermann;Rebecca Asher

Frequent Co-Authors

Giovanni Scambia
Giovanni Scambia Catholic University of the Sacred Heart
Nicoletta Colombo
Nicoletta Colombo University of Milano-Bicocca
Domenica Lorusso
Domenica Lorusso Catholic University of the Sacred Heart
Gabriella Ferrandina
Gabriella Ferrandina Catholic University of the Sacred Heart
Ugo De Giorgi
Ugo De Giorgi The University of Texas MD Anderson Cancer Center
Isabelle Ray-Coquard
Isabelle Ray-Coquard Claude Bernard University Lyon 1
Jonathan A. Ledermann
Jonathan A. Ledermann University College London
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Christian Marth
Christian Marth Innsbruck Medical University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Expanding career options beyond medicine is a smart choice for anyone interested in healthcare. There are a variety of related online degrees and pathways that provide flexibility, affordability, and multiple opportunities for growth. Many aspiring professionals start with an online healthcare administration degree, designed to develop essential skills for managing medical organizations or clinics.

For those with a bachelor's degree aiming for leadership roles, affordable online mha programs make it possible to advance without stepping away from work or family commitments. Nurses ready to reach the highest clinical level can benefit from accredited msn to dnp programs online, enabling them to become clinical leaders and influence healthcare policy and practice.

Pharmacists can also further their education through an online pharmd, opening doors to advanced pharmacy roles in research, policy, and management. Choosing any of these related online degrees boosts credentials and expands career opportunities in the rapidly evolving field of healthcare.

Best Scientists Citing Sandro Pignata

Trending Scientists

Recently Published Articles